Search
LENZ Therapeutics Inc
LENZAdd to Watchlist
3.715USD
-0.045-1.20%
Market hours 09/24, 13:52（ET）
116.47MMarket Cap
LossP/E TTM
About LENZ Therapeutics Inc Company
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ Therapeutics Inc Profile
Ticker SymbolLENZ
Company nameLENZ Therapeutics Inc
IPO dateJun 25, 2021
CEOSchimmelpennink (Evert)
Number of employees42
Security typeOrdinary Share
Fiscal year-endJun 25
Address- -
City- -
Stock exchangeNASDAQ OMX - NASDAQ BASIC
Country- -
Postal code- -
Phone- -
Website- -
Ticker SymbolLENZ
IPO dateJun 25, 2021
CEOSchimmelpennink (Evert)
Company Executives of LENZ Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
FAQs
Who are the top five shareholders of LENZ Therapeutics Inc?
The top five shareholders of LENZ Therapeutics Inc are: Mr. Marc Odrich
How many institutions hold shares of LENZ Therapeutics Inc (LENZ)?
As of 2026Q1, 347 institutions hold shares of LENZ Therapeutics Inc, with a combined market value of approximately 36.30M, accounting for 115.82% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 853081.00.